Even though HER2 is emerging as a promising target for advanced NSCLC, its role has not yet been confirmed. Thus, ESMO recommends that patients with metastatic HER2-mutated NSCLC should be enrolled in a clinical trial. Recruiting trials of targeted therapy for HER2-mutated NSCLC include DESTINY-Lung02 and a phase 2 trial of ado-trastuzumab emtansine for patients with HER2 amplified or mutant cancers. Search for additional clinical trials here. ESMO guidelines can be accessed here.
Learn more about targeting HER2 in NSCLC.
Editor's Recommendations
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Maurie Markman. Fast Five Quiz: ERBB2 (HER2) Mutation in Non-Small Cell Lung Cancer - Medscape - Nov 23, 2021.
Comments